IMAXIO S.A. news

Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million.

Osivax was recently created as a spin-off of the R&D department of Imaxio, a biotech company also based in Lyon. The objectives of the spin-off are to enable Osivax to focus on the development of the R&D platform and Imaxio to accelerate the commercial development of its leptospirosis vaccine commercialized curr

Imaxio, a biotech company specializing in immunology announces today that it has signed a license agreement with the world-renowned German Cancer Research Center (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

It follows a 2-year evaluation of Imaxio’s IMX313P pro-immunogenic technology by DKFZ under a license option agreement. This evaluation has proven the ability of IMX313P to enhance the efficacy

Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.

This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836.

Imaxio’s influenza vaccine candidate IMX836 is being developed as an add-on to seasonal vaccines, in order to i

Imaxio, a biotech company specializing in immunology announces today the sale of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. The transaction was facilitated by CMC Consulting Group.

This sale is aligned with Imaxio’s willingness to refocus its business on vaccines. This is the result of several years of work by Imaxio’s teams, which have increased Trolovol®’s turnover since its

Imaxio, a biotech company specialising in immunology, announces today the execution of a license agreement with AJ Biologics, a Malaysian company dedicated to vaccine manufacturing and commercialization, as part of the company’s strategy to extend the distribution of Imaxio’s leptospirosis vaccine in Malaysia.

Imaxio is a French SME developing an early clinical stage pipeline of vaccine candidates based on its proprietary technology named IMX313, as well as commercialising